Project Grant R01HL176850
Award Date
1/1/25
Completion Date
11/30/28
Dollars Obligated
$766K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Yale Univ (FL6GV84CKN57)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Connecticut, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to evaluate methods for improving the homing and engraftment efficiency of CD34+ cells from sickle cell disease (SCD) patients. The $128,100 award to the New York Blood Center, Inc. will support research to determine if co-infusing the CD34+ cells with their flow-through accessory cells, normally discarded after CD34+ cell...
This Project Grant award, valued at $607,535, was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to investigate the effects of the breakdown product hemin on the pulmonary endothelium and its contribution to the pulmonary complications of sickle cell disease, including acute chest syndrome and pulmonary hypertension. The research aims to evaluate the specific effects of...
This Project Grant award of $179,280 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to the University of Pennsylvania supports research investigating the impact of diet and nutritional stress on neutrophil function and sickle cell disease pathology. The project aims to evaluate how early life nutritional exposures shape neutrophil development and function, and how this in turn modulates the severity of sickle cell disease. By leveraging...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $827,753.90 to Bloodworks, a non-profit organization in Seattle, to conduct research on oxidative cysteine modification by thiol isomerases and its role in vaso-occlusive events in sickle cell disease. The research aims to mechanistically examine how protein disulfide isomerase (PDI) senses the redox environment in sickle cell disease, catalyze electron...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $608,126 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the Regents of the University of Minnesota to develop and validate single-cell biomarkers for predicting clinical outcomes in sickle cell disease (SCD). The project aims to (1) define the relationship between common SCD adverse clinical outcomes and single-cell biochemical and mechanical properties, (2) determine the relationship between treatment responses...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research program) provides $483,852 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a high-throughput platform technology for measuring the kinetics and equilibrium concentration of sickle hemoglobin polymerization in single red blood cells. The platform will enable optimization of emerging sickle cell disease treatments, such as...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $300,000 to Gigamune, Inc. to develop an in vivo gene therapy for sickle cell disease. The project aims to test a novel lentiviral vector technology for efficiently editing hematopoietic stem cells to knockout the BCL11A enhancer, a key genetic target for sickle cell treatment. Through in vitro assays, the Phase I effort will...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $445,000.00 to The Children's Hospital Of Philadelphia Research Institute to conduct research on the role of neutrophil extracellular traps (NETs) in thromboinflammatory diseases. The key objectives are to: 1) characterize the role of NETs in immune homeostasis, 2) define the mechanism by which platelet factor 4 (PF4) and an Fc-modified antibody enhance NET-mediated...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $202,366 to Emory University to investigate the role of heme-induced complement activation in sickle cell disease (SCD) pregnancy. The primary objectives are to: 1) Characterize the effects of SCD and heme-induced complement activation on pregnancy outcomes in a mouse model of SCD (K99 phase), and 2) Determine if heme and/or complement modulation can improve...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $637,526 to Duke University to conduct research on the role of sickle red blood cells (RBCs) in activating neutrophils and promoting vaso-occlusion in sickle cell disease (SCD). The key objectives of the research are to: 1) delineate the characteristics of sickle RBCs that contribute to neutrophil activation, 2) examine the...